[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"BioGaia AB\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":152},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,72,102,127],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100647962","an-open-label-single-arm-interventional-study-to-evaluate-the-safety-and-efficacy-of-a-probiotic-containing-cream-in-children-with-dry-skin-100647962",false,"NCT07713303","An Open-label, Single-arm Interventional Study to Evaluate the Safety and Efficacy of a Probiotic-containing Cream in Children With Dry Skin","DERMA KIDS","Inclusion Criteria:\n\n1. Newborn - 7 years.\n2. ODS ≥ 2 in the target area.\n3. Parent\u002Fguardian able to comply with weekly diaries\u002Fphotos and visits.\n4. Signed ICF by parent\u002Flegal guardian; assent as required.\n\nExclusion Criteria:\n\n1. Topical medicated treatments on target area within 2 weeks.\n2. Active skin infection or severe eczema flare at target site.\n3. Known allergy to product components.\n4. Participation in another study within 30 days.\n5. Any condition judged by investigator to preclude participation.","ALL","0 Months","7 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","The DermaKIDS study is an open-label, single-arm interventional study designed to evaluate the safety and efficacy of a probiotic-containing cream in children with dry skin. Approximately 40 children aged from newborn to 7 years will be enrolled at two study sites in Portugal. Participants will apply the study cream twice daily for a period of four weeks under normal home-use conditions. The primary efficacy endpoint is the change in Overall Dry Skin Score (ODS) from baseline to the end of the study. Safety and efficacy will be assessed through investigator evaluations combined with weekly parent-reported diaries and standardized photographs.",[27],"Dry Skin",[29,30,31,32,33],"dry skin","probiotic","pediatric","ODS","ointment","NOT_YET_RECRUITING","2026-07-14",{"date":37,"type":38},"2026-07-20","ACTUAL",{"date":40,"type":21},"2026-09-01",{"date":42,"type":21},"2027-02-01",{"name":44,"class":45},"BioGaia AB","INDUSTRY",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":4},"100645555","efficacy-and-tolerability-of-a-probiotic-ointment-100645555","NCT07701447","Efficacy and Tolerability of a Probiotic Ointment","Inclusion Criteria Male and female pediatric patients aged 0.5 years to 15 years with Atopic Dermatitis.\n\nSCORAD Index at D0 = 15 to 50, inclusive. In goodgeneral health as reported by the parent(s)\u002Flegal representative(s). Available for the full duration of the study and willing to comply with procedures.\n\nSubjects whose parents or legal representative are willing to sign the informed consent.\n\nExclusion Criteria Use of phototherapy for atopic dermatitis. Use of systemic corticosteroids within 2 weeks prior to the study. Use of Immunosuppressive or cytostatic drugs within 1 months prior to the study.\n\nUse of antibiotics (topical and systemic) within 15 days prior to the start of the study.\n\nSubjects who are treated with vitamin A-derived compounds or other topical medications for acne in the experimental area during the 30 days prior to the start of the study.\n\nHistory of sensitivity to the study products, or its components. History or evidence of allergies requiring acute or chronic treatment (except seasonal allergic rhinitis).\n\nSubjects with active infection in atopic dermatitis areas requiring antibiotics, antifungals, or antiviral agents within 7 days before baseline participation in any study that would interfere with the current study.\n\nFever (temperature\\> 37.5 °C axillary or equivalent) during 48 hours prior the start of the study.\n\nPathologies associated with immunodeficiency or cancer processes. Any concurrent dermatologic or medical conditions that may interfere with the investigators ability to assess the subject's response to the study drug or require the continued use of topical corticosteroids.\n\nSubjects who have received the schedule MMR vaccination during the study period or have received the last dose within three weeks prior the start of the study.\n\nSubjects who participates in any study that would interfere with the current study.","6 Months","15 Years",{"count":56,"type":21},92,[24],"This study evaluates the tolerability and efficacy of a probiotic ointment compared with a comparator lotion in children with atopic dermatitis.",[60],"Atopic Dermatitis",[60,62,63,64],"Probiotic","Microbiome","Ointment",{"date":66,"type":38},"2026-07-15",{"date":68,"type":21},"2026-08",{"date":70,"type":21},"2028-11",{"name":44,"class":45},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":89,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100638747","influence-of-probiotics-on-early-gut-microbial-colonization-100638747","NCT07608341","Influence of Probiotics on Early Gut Microbial Colonization","Influence of Probiotics on Early Gut Microbial Colonization, Safety and Tolerability in Infants Born by Caesarean Section","STORKIE","Inclusion Criteria:\n\nInfant born by planned C-section or vaginal born infant\n\nGestational age at birth ≥ 37±0 weeks to \\\u003C41 ±0 weeks\n\nInfant Apgar score 7-10, (5 minutes after birth)\n\nIntention to breastfeed the infant\n\nParents\u002Flegal guardians are \\>18 years\n\nParents\u002Flegal guardians have readiness and the opportunity to fill out a study diary, questionnaires and agree to collect biological samples\n\nParents\u002Flegal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator\n\nParents\u002Flegal guardians are willing and able to give written informed consent for their and their infants participation in the study\n\nExclusion Criteria:\n\n\\>72 hours after birth when collecting the first faecal sample and given the first drops of study product\n\nInfants classified as small for gestational age (SGA), defined as birth weight \\\u003C -2 standard deviations (SD) for gestational age and sex according to national reference standards.\n\nInfants with birth of congenital malformations or anomalies\n\nInfants not able to feed adequately by oral means at the time of screening (i.e., requiring tube feeding)\n\nInfants requiring care in neonatal unit\n\nDisruption of amniotic membranes for \\>24 hours\n\nInfants consuming probiotics, including in infant formula\n\nMothers use of antibiotics during the last 14 days of pregnancy prior to delivery\n\nParticipation in other clinical studies\n\nAny other disease, condition, or circumstance that, in the investigator's opinion, may compromise the participant's safety, adherence to the protocol, or the interpretation of study results",true,"0 Days","3 Days",{"count":84,"type":21},150,[24],"The goal of this clinical trial is to learn whether daily probiotic drops plus vitamin D3 can improve early gut microbiome colonization in healthy infants born by C-section. It will also assess safety and tolerability.\n\nAn intervention with probiotics + vitamin D3 will be compared to placebo + vitamin D3 in a double-blind, randomized design, and include an open-label vaginal-born reference group.\n\nParticipants will receive study drops daily for 8 weeks and provide stool samples at multiple time points and complete questionnaires\u002Fdiaries. After the intervention period, there is an optional follow-up period for up to 3 years.",[88],"C-Section",[90,91,30,92],"microbiome","c-section","gut microbiome","2026-05-19",{"date":95,"type":38},"2026-05-27",{"date":97,"type":21},"2026-08-01",{"date":99,"type":21},"2030-08-01",{"name":44,"class":45},2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":4,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},"100607615","evaluating-the-effect-of-probiotic-limosilactobacillus-reuteri-l-reuteri-on-crying-and-fussing-time-in-infants-with-colic-100607615","NCT07190859","Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic","A Double-blind, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic","Inclusion Criteria:\n\n1. Aged between 3-12 weeks at screening.\n2. Gestational age 37+0 weeks - 42+0 weeks at birth.\n3. Birth weight appropriate for gestational age (AGA - weight between 10th and 90th percentile) or Large for Gestational Age (LGA - weight above the 90th percentile) determined using WHO Weight-for Age percentile guides.\n4. Parents\u002Fcaregivers\u002Flegal guardians are \\>18 years.\n5. Exclusively or predominantly breastfed infants (\\> 50 % breast fed).\n6. Willing to maintain current feeding patterns (not change formula\u002Fnot change ratio of formula:breast milk etc.).\n7. Readiness and the opportunity for parents\u002Fcaregivers\u002Flegal guardians to fill out a study diary, questionnaires.\n8. Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with a physician, parents\u002Fcaregivers\u002Flegal guardians must report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24-hour period should show 3 or more hours of crying\u002Ffussing time.\n9. Parents\u002Fcaregivers\u002Flegal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator.\n10. Parents\u002Fcaregivers\u002Flegal guardians willing and able to give informed consent for their and their infant's participation in the study.\n11. The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 3 (Day 8), and Visit 4 (Day 22).\n12. Infant is considered healthy, in the opinion of the investigator following physical exam.\n\nExclusion Criteria:\n\n1. Infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk \\> 8 times daily, projectile, bilious or bloody emesis).\n2. Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container \\> 12x in breastfed and \\>5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents\u002Fcaregivers\u002F legal guardians.\n3. Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease.\n4. Infants with reported exposure to probiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.\n5. Infants with reported exposure to oral and\u002For systemic antibiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.\n6. Infants with reported exposure to medications, therapies, or products with the aim to relieve infantile colic including proton pump inhibitors in the 7 days prior to Screening Visit (V1) and throughout the study period.","3 Weeks","12 Weeks",{"count":112,"type":21},50,[24],"This is a double-blind, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying and fussing time.",[116],"Infantile Colic","RECRUITING","2025-09-23",{"date":120,"type":38},"2025-09-24",{"date":122,"type":38},"2025-08-04",{"date":124,"type":21},"2026-08-30",{"name":44,"class":45},4,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":16,"minAge":109,"maxAge":134,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":141,"overallStatus":117,"whyStopped":4,"lastUpdateSubmitDate":144,"lastUpdatePostDateStruct":145,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":101},"100478612","effect-of-probiotic-limosilactobacillus-reuteri-l-reuteri-on-crying-time-in-infants-with-colic-100478612","NCT05512234","Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying Time in Infants With Colic","A Double-blind, Mylti-center, Randomised, Placebo-controlled, Parallel-group Study Evaluating the Effect of Probiotic Limosilactobacillus Reuteri (L. Reuteri) on Crying and Fussing Time in Infants With Colic","Inclusion Criteria:\n\n1. Aged between 3-8 weeks at screening.\n2. Gestational age 37+0 weeks - 42+0 weeks at birth.\n3. Birth weight appropriate for gestational age (AGA - weight between 10th and 90th percentile) or Large for Gestational Age (LGA - weight above the 90th percentile) determined using WHO Weight-for Age percentile guides.\n4. Parents\u002Fcaregivers\u002Flegal guardians are \\>18 years.\n5. Exclusively or predominantly breastfed infants (\\> 50 % breast fed).\n6. Willing to maintain current feeding patterns (not change formula\u002Fnot change ratio of formula:breast milk etc.).\n7. Readiness and the opportunity for parents\u002Fcaregivers\u002Flegal guardians to fill out a study diary, questionnaires.\n8. Infantile colic diagnosed according to Rome IV criteria (face-to-face consult with a physician, parents\u002Fcaregivers\u002Flegal guardians must report that their infant has cried or fussed for 3 or more hours per day, during 3 or more days in the preceding week). At Visit 2, this will be confirmed by Baby's Day Diary®, at least one 24-hour period should show 3 or more hours of crying\u002Ffussing time.\n9. Parents\u002Fcaregivers\u002Flegal guardians with ability to understand and comply with the requirements of the study, as judged by the Investigator.\n10. Parents\u002Fcaregivers\u002Flegal guardians willing and able to give informed consent for their and their infant's participation in the study.\n11. The mother of the infant must be willing to attend Visit 2 (Day 0), Visit 4 (Day 8), and Visit 6 (Day 22).\n12. Infant is considered healthy, in the opinion of the investigator following physical exam.\n\nExclusion criteria\n\n1. Infants with severe gastroesophageal reflux (throwing up or spitting up more than a teaspoon of milk \\> 8 times daily, projectile, bilious or bloody emesis).\n2. Infants with failure to thrive, intrauterine growth retardation, haematochezia (blood in the stools), diarrhoea (watery stools that takes the shape of a container \\> 12x in breastfed and \\>5 in partially breastfed infants daily), or fever (38.0 degrees), as reported by parents\u002Fcaregivers\u002Flegal guardians.\n3. Infants with congenital heart disease, immunodeficiency, asplenia, cancer, cystic fibrosis, and those with liver disease.\n4. Infants with reported exposure to probiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.\n5. Infants with reported exposure to oral and\u002For systemic antibiotics in the 7 days prior to Screening Visit (V1) and throughout the study period.\n6. Infants with reported exposure to medications, therapies, or products with the aim to relieve infantile colic including proton pump inhibitors in the 7 days prior to Screening Visit (V1) and throughout the study period.","8 Weeks",{"count":136,"type":21},102,[24],"This is a double-blind, multi-center, randomized, placebo-controlled, parallel-group study in infants with colic with the primary objective to evaluate crying time.",[140],"Colic, Infantile",[142,143],"Colic","L. reuteri","2025-09-17",{"date":146,"type":38},"2025-09-22",{"date":148,"type":38},"2022-07-13",{"date":150,"type":21},"2025-10-30",{"name":44,"class":45},""]